Document:

Exhibit 10.33

 

EXECUTION VERSION

 

AMENDMENT NO. 1 TO AMENDED AND RESTATED

VENTURE LOAN AND SECURITY AGREEMENT AND TO SECURED PROMISSORY NOTES

 

This AMENDMENT NO.
1 TO THE AMENDED AND RESTATED VENTURE LOAN AND SECURITY AGREEMENT AND TO SECURED PROMISSORY NOTES (this “Amendment”),
dated as of September 10, 2019, is entered into by and among TITAN PHARMACEUTICALS, INC. (“Borrower”), HORIZON
CREDIT II LLC (“Horizon”), L. MOLTENI & C. DEI F.LLI ALITTI SOCIETÀ DI ESERCIZIO S.P.A. (“Molteni”
and together with Horizon, each a “Lender” and collectively the “Lenders”), and Molteni as
collateral agent (the “Collateral Agent”) for the Lenders.

 

RECITALS

 

A.       Borrower,
Lenders and Collateral Agent are parties to a certain Amended and Restated Venture Loan and Security Agreement dated as of March
21, 2018 (as amended, restated, supplemented or otherwise modified from time to time (including by this Amendment), the “Loan
Agreement”).

 

B.       In
connection with the transactions contemplated by the Loan Agreement, Borrower issued in favor of (1) Horizon a Secured Promissory
Note dated March 21, 2018 in the original principal amount of $1,600,000 (the “Horizon Note”) and (2) Molteni
a Secured Promissory Note dated March 21, 2018 in the original principal amount of $2,400,000 (the “Molteni Note”
and together with the Horizon Note, each a “Note” and collectively the “Notes”).

 

C.       Borrower,
Lenders and Collateral Agent desire to amend the Loan Agreement and the Notes on the terms, and subject to the conditions, set
forth herein.

 

AGREEMENT

 

NOW, THEREFORE, in
consideration of the above recitals and for other good and valuable consideration, the receipt and adequacy of which are hereby
acknowledged, Borrower, Lenders and Collateral Agent hereby agree as follows:

 

1.            Definitions;
Interpretation. Unless otherwise defined herein, all capitalized terms used herein and defined in the Loan Agreement shall
have the respective meanings given to those terms in the Loan Agreement. Other rules of construction set forth in the Loan Agreement,
to the extent not inconsistent with this Amendment, apply to this Amendment and are hereby incorporated by reference.

 

2.            Confirmation.
Borrower hereby acknowledges and agrees that: (i) the Loan Agreement and the Notes set forth the legal, valid, binding and continuing
obligations of Borrower to Lenders, (ii) the Obligations to Lenders under the Loan Agreement and the Notes are secured by validly
perfected security interests in all assets of Borrower, the effectiveness and validity of which are hereby confirmed and (iii)
Borrower has no cause of action, claim, defense or set-off against Lenders or any of their respective affiliates and subsidiaries,
officers, directors, employees, shareholders, agents and representatives (“Related Parties”), arising on or
prior to the date of this Amendment, in any way regarding or relating to the Loan Agreement, the Notes or Lenders’ or their
respective Related Parties’ actions thereunder and to the extent any such cause of action, claim, defense or set-off ever
existed, whether foreseen or unforeseen, it is waived and Lender and its Related Parties are released from any such causes of action,
claims, defenses or rights of set-off of Borrower.

 

     

     

    

 

3.            Amendments
to Loan Agreement. Borrower, Lenders and Collateral Agent hereby agree that the Loan Agreement is amended as follows:

 

(a)           Section
1.1 of the Loan Agreement is hereby amended by inserting the following new definitions in the appropriate alphabetical order:

 

“Conversion
Cap” has the meaning given such term in Section 2.5(a) of this Agreement.

 

“Conversion
Price” means the lesser of (i) $0.74 or (ii) in the event of a Qualified Equity Financing, the price per share sold in
such Qualified Equity Financing.

 

“Horizon
Priority Cap” means, at any time, the lesser of (1) $1,000,000 or (2) the then outstanding principal balance of the Horizon
Loan.

 

“Qualified
Equity Financing” means the sale of shares of common stock of the Borrower pursuant to which the Borrower receives, prior
to December 31, 2019, gross cash proceeds of at least $10,000,000.

 

(b)           The
defined term “Maturity Date” set forth in Section 1.1 of the Loan Agreement is hereby amended and restated in its entirety
to provide as follows:

 

“Maturity
Date” means, with respect to each Loan, June 1, 2022, or if earlier, the date of acceleration of such Loan following
an Event of Default or the date or prepayment, whichever is applicable.”

 

(c)           Section
2.2(g)(i) of the Loan Agreement is hereby amended by deleting the reference to “Two Hundred Forty-Six Thousand Seven Hundred
Thirty-Nine and 00/100 Dollars ($246,739)” in the first sentence thereof and replacing the same with “Three Hundred
Seventy-One Thousand Seven Hundred Thirty-Nine and 00/100 Dollars ($371,739)”.

 

(d)           Section
2.2(g)(ii) of the Loan Agreement is hereby amended by deleting the reference to “Four Hundred Sixty Three Thousand Two Hundred
Sixty-One and 00/100 Dollars ($463,261)” in the first sentence thereof and replacing the same with “Six Hundred Fifty
Thousand Seven Hundred Sixty-One and 00/100 Dollars ($650,761)”.

 

(e)           Section
2.2 of the Loan Agreement is hereby amended by inserting the following new clause (i) immediately after clause (h) thereof:

 

“(i) Restructuring
Fee. Borrower shall pay to Horizon a payment in the amount of Fifty Thousand and 00/100 Dollars ($50,000) upon the earlier
of (A) payment in full of the Horizon Loan, (B) an Event of Default and demand by the Required Lenders of payment in full of the
Loans or (C) the Maturity Date, as applicable.”

 

    2 

     

    

 

(f)           Section
2.5(a) of the Loan Agreement is hereby amended and restated in its entirety to provide as follows:

 

“At any
time or from time to time during the period following the Restatement Effective Date through the Maturity Date, Molteni shall have
the right and option (“Conversion Option”), exercisable by written notice (a “Conversion Notice”)
to Borrower to (i) convert any portion or all Obligations outstanding under the Molteni Loan on the desired conversion date specified
in the Conversion Notice into a number of shares (the “Conversion Shares”) of common stock (the “Conversion
Stock”) of Borrower equal to the aggregate amount of such Obligations being converted, divided by the Conversion Price,
and (ii) pursuant to such conversion, issue the Conversion Shares as contemplated by this Section 2.5. Notwithstanding the foregoing,
in no event shall Molteni be entitled to exercise its Conversion Option for more than Three Million Four Hundred Twenty-Two Thousand
Seven Hundred Seventy-Seven (3,422,777) Conversion Shares in the aggregate (the “Conversion Cap”). All Obligations
not converted in accordance with this Section 2.5(a) shall be due and payable in accordance with the terms of the Loan Agreement
and the Molteni Note. The Conversion Price and the Conversion Cap shall be subject to adjustment for stock splits, combinations,
recapitalizations and similar events.”

 

(g)           Section
9.1 of the Loan Agreement is hereby amended by (1) deleting the reference to “December 31, 2019” in the first sentence
thereof and replacing the same with “December 31, 2020” and (2) deleting the reference to “January 1, 2020”
in the second sentence thereof and replacing the same with “January 1, 2021.”

 

(h)          Section
9.7 of the Loan Agreement is hereby amended and restated in its entirety to provide as follows:

 

“Application
of Collateral Proceeds. The proceeds and/or avails of the Collateral, or any part thereof (as well as any other amounts of
any kind held by Collateral Agent or any Lender, at the time of or received by Collateral Agent or any Lender after the occurrence
of an Event of Default hereunder) shall be paid to and applied as follows:

 

(a)       First,
to the payment of out-of-pocket costs and expenses, including all amounts expended to preserve the value of the Collateral, of
foreclosure or suit, if any, and of such sale and the exercise of any other rights or remedies, and of all proper fees, expenses,
liability and advances, including reasonable legal expenses and attorneys’ fees, incurred or made hereunder by Collateral
Agent or any Lender, including Lender’s Expenses;

 

(b)       Second,
if a Qualified Equity Financing has occurred, to the payment to Horizon of the amount then owing or unpaid on the Horizon Loan
for any accrued and unpaid interest, the amounts which would have otherwise come due under Section 2.3(b)(ii), if the Horizon
Loan had been voluntarily prepaid, the principal balance of the Horizon Loan, and all other Obligations with respect to the Horizon
Loan; provided that all payments made to Horizon pursuant to this Section 9.7(b) and Section 9.11(b) shall not, collectively,
exceed the Horizon Priority Cap at any time.

 

    3 

     

    

 

(c)       Third,
to the payment to Lenders of the amount then owing or unpaid on the Loans for any accrued and unpaid interest, the amounts which
would have otherwise come due under Section 2.3(b)(ii), if the Loans had been voluntarily prepaid, the principal balance
of the Loans, and all other Obligations with respect to the Loans (provided, however, if such proceeds shall be insufficient
to pay in full the whole amount so due, owing or unpaid upon the Loans, then first, to the unpaid interest thereon ratably
(after giving effect to any payments made pursuant to Section 9.7(b) and 9.11(b)), second, to the amounts which would have
otherwise come due under Section 2.3(b)(ii) ratably (after giving effect to any payments made pursuant to Section 9.7(b)
and 9.11(b)), if the Loans had been voluntarily prepaid, third, to the principal balance of the Loans ratably (after giving
effect to any payments made pursuant to Section 9.7(b) and 9.11(b)), and fourth, to the ratable payment (after giving effect
to any payments made pursuant to Section 9.7(b) and 9.11(b)) of other amounts then payable to any Lender under any of the Loan
Documents); and

 

(d)       Fourth,
to the payment of the surplus, if any, to Borrower, its successors and assigns or to the Person lawfully entitled to receive the
same.”

 

(i)           Section
9.11 of the Loan Agreement is hereby amended and restated in its entirety to provide as follows:

 

“Application
of Proceeds. Until the discharge of the Obligations to the Collateral Agent and all Lenders, and regardless of whether the
Borrower become the subject of a bankruptcy or insolvency proceeding or any action or proceeding of the type described in Sections
8.13 or 8.14 hereof, Collateral or proceeds received in connection with an Enforcement Action or in connection with any bankruptcy
or insolvency proceeding or any action or proceeding of the type described in Sections 8.13 or 8.14 hereof involving the Borrower
will be applied

 

(a)       First,
to the Collateral Agent for the payment in full to the Collateral Agent for its expenses of collection and enforcement, or of repossession,
holding, preparation, and disposition of any Collateral, including attorney fees and expenses,

 

(b)       Second,
to the Collateral Agent for the payment in full of the other Obligations secured by the Lien on the Collateral, and, if a Qualified
Equity Financing has occurred and the Collateral and proceeds received are in connection with any an bankruptcy or insolvency proceeding
or any action or proceeding of the type described in Sections 8.13 or 8.14 hereof involving the Borrower, the Collateral Agent
shall distribute all or a portion of such payment to Horizon; provided that all payments made to Horizon pursuant to this
Section 9.11(b) and Section 9.7(b) shall not, collectively, exceed the Horizon Priority Cap at any time;

 

(c)       Third,
to the Collateral Agent for the payment in full of the other Obligations secured by the Lien on the Collateral, and the Collateral
Agent shall distribute such payment to the Lenders (other than any Lender that has consented in writing to waive its pro rata
share of such payment) and itself, pro rata (after giving effect to any payments made pursuant to Section 9.7(b) and 9.11(b))
based upon their respective shares, if any, of the Obligations with respect to which such payment was received; and

 

    4 

     

    

 

(d)       Fourth,
to the Collateral Agent for payments to be made in the Collateral Agent’s discretion in accordance with applicable law, including
the UCC.

 

Each of the
Lenders agrees that, if it should receive any amount hereunder (whether by voluntary payment, by realization upon security, by
the exercise of the right of setoff or banker’s lien, by counterclaim or cross action, by the enforcement of any right under
the Loan Documents, or otherwise) which is applicable to the payment of the principal of, or interest on, the Loans, of a sum which
with respect to the related sum or sums received by other Lenders is in a greater proportion than the total of such Obligation
then owed and due to such Lender bears to the total of such Obligation then owed and due to all of the Lenders immediately prior
to such receipt, then such Lender receiving such excess payment shall promptly transfer such excess amount to the Collateral Agent
for distribution as provided hereunder. Each Lender will be deemed, by its acceptance of the benefits of the Collateral and of
the guarantees (if any) of the Obligations, to have agreed to the provisions of this Section 9.11.”

 

4.            Amendments
to Notes. Borrower, Lenders and Collateral Agent hereby agree that each Note is hereby amended as follows:

 

(a)          The
reference to “December 1, 2019” in the fourth sentence of the second paragraph of each Note is hereby deleted and replaced
with “December 1, 2020.”

 

(b)           The
reference to “January 1, 2020” in the fifth sentence of the second paragraph of each Note is hereby deleted and replaced
with “January 1, 2021.”

 

(c)          The
reference to “Two Hundred Forty-Six Thousand Seven Hundred Thirty-Nine and 00/100 Dollars ($246,739)” in the sixth
sentence of the second paragraph of the Note with respect to the Horizon Loan is hereby deleted and replaced with “Three
Hundred Seventy-One Thousand Seven Hundred Thirty-Nine and 00/100 Dollars ($371,739).”

 

(d)          The
reference to “Four Hundred Sixty Three Thousand Two Hundred Sixty-One and 00/100 Dollars ($463,261)” in the sixth sentence
of the second paragraph of the Note with respect to the Molteni Loan is hereby deleted and replaced with “Six Hundred Fifty
Thousand Seven Hundred Sixty-One and 00/100 Dollars ($650,761).”

 

5.            Reversion
of Certain Amendments. If the Qualified Equity Financing does not occur, the addition of the defined term “Horizon Priority
Cap” in Section 3(a) and the amendments set forth in Sections 3(b), 3(g), 3(h), 3(i), 4(a) and 4(b) above shall all revert,
terminate and be of no further force or effect as of December 31, 2019.

 

    5 

     

    

 

6.            Representations
and Warranties. Borrower hereby represents and warrants as follows:

 

(a)          At
and as of the date of this Amendment and immediately prior to and after giving effect to this Amendment, each of the representations
and warranties contained in the Loan Agreement is true and correct in all material respects (except where such representations
and warranties expressly relate to an earlier date, in which case such representations and warranties are true and correct in all
material respects as of such earlier date).

 

(b)          Borrower
has all necessary power and authority to execute, deliver and perform in accordance with the terms of this Amendment and has the
requisite power and authority to own and operate its Property and to carry on its business as now conducted.

 

7.            Effect
of Agreement. On and after the date hereof, each reference to the Loan Agreement and the Notes in the Loan Agreement or in
any other Loan Document shall mean the Loan Agreement and each Note as amended by this Amendment. Except as expressly provided
hereunder, the execution, delivery and effectiveness of this Amendment shall not operate as a waiver of any right, power, or remedy
of any Lender, nor constitute a waiver of any provision of the Loan Agreement or of any Note. Except as expressly provided herein,
nothing contained herein shall, or shall be construed to (nor shall the Borrower ever argue to the contrary) (i) modify the Loan
Agreement, any Note or any other Loan Document (ii) modify, waive, impair, or affect any of the covenants, agreements, terms, and
conditions thereof, or (iii) waive the due keeping, observance and/or performance thereof, each of which is hereby ratified and
confirmed by the Borrower. Except as amended above, the Loan Agreement and each Note remain in full force and effect.

 

8.             Headings.
Headings in this Amendment are for convenience of reference only and are not part of the substance hereof.

 

9.            Governing
Law. This Amendment shall be governed by and construed in accordance with the laws of the State of New York without reference
to conflicts of law rules.

 

10.          Counterparts.
This Amendment may be executed in any number of counterparts, including by electronic or facsimile transmission, each of which
when so delivered shall be deemed an original, but all such counterparts taken together shall constitute but one and the same instrument.

 

11.          Integration.
This Amendment and the Loan Documents constitute and contain the entire agreement of Borrower, Collateral Agent and Lenders with
respect to their respective subject matters, and supersede any and all prior agreements, correspondence and communications.

 

[Remainder of page intentionally left blank]

 

    6 

     

    

 

IN WITNESS WHEREOF,
Borrower, Lenders and Collateral Agent have caused this Amendment to be executed as of the day and year first above written.

 

	 	BORROWER:
	 	 
	 	TITAN PHARMACEUTICALS, INC.
	 	 
	 	By:	/s/ Sunil Bhonsle
	 	 	Name:  	Sunil Bhonsle
	 	 	Title:	Chief Executive Officer

 

	 	LENDERS:
	 	 
	 	HORIZON CREDIT II LLC
	 	 
	 	By:	/s/ Robert D. Pomeroy
	 	 	Name:  	Robert D. Pomeroy, Jr.
	 	 	Title:  	Chief Executive Officer

 

	 	L. MOLTENI & C. DEI F.LLI ALITTI SOCIETÀ DI ESERCIZIO S.P.A.
	 	 	 
	 	By:	/s/ Gaetano Ieovelella
	 	 	Name:	Gaetano Ieovelella
	 	 	Title:  	Chief Financial Officer

 

	 	COLLATERAL AGENT:
	 	 	 
	 	L. MOLTENI & C. DEI F.LLI ALITTI SOCIETÀ DI ESERCIZIO S.P.A.
	 	 	 
	 	By:	/s/ Gaetano Ieovelella
	 	 	Name:  	Gaetano Ieovelella
	 	 	Title:  	Chief Financial Officer

 

    7Exhibit 10.34

 

CONFIDENTIAL
TREATMENT REQUESTED.

INFORMATION
FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN

REQUESTED
IS OMITTED AND MARKED WITH “[*******]” OR OTHERWISE

CLEARLY
INDICATED. AN UNREDACTED VERSION OF THIS DOCUMENT HAS

ALSO
BEEN PROVIDED TO THE SECURITIES AND EXCHANGE COMMISSION.

 

AMENDMENT NO. 2 TO ASSET PURCHASE, SUPPLY
AND SUPPORT AGREEMENT

 

THIS AMENDMENT NO. 2 TO ASSET PURCHASE,
SUPPLY AND SUPPORT AGREEMENT (this “Amendment”) is entered into as of September 10, 2019 (the “Effective
Date”), by and between MOLTENI & C. DEI F.LLI ALITTI SOCIETÀ DI ESERCIZIO S.P.A., a company organized and
existing under the laws of Italy having its principal office at Strada Statale 67, Frazione Granatieri, Scandicci (Florence), Italy
(“Molteni”), and TITAN PHARMACEUTICALS, INC., a corporation organized and existing under the laws of the State
of Delaware and having its principal office at 400 Oyster Point Blvd., Suite 505, South San Francisco, CA 94080-1921, United States
(“Titan”), each a “Party” and collectively, the “Parties”. All capitalized terms used
but not defined herein shall have the meanings ascribed to them in the Agreement (as defined below).

 

WHEREAS, Molteni and Titan are parties to
that certain Asset Purchase, Supply and Support Agreement, dated as of March 21, 2018 (as amended by that certain Amendment No.
1 to the Asset Purchase, Supply and Support, dated as of August 3, 2018, the “Agreement”); and

 

WHEREAS, Molteni and Titan have agreed to
enter into an amendment of even date herewith to the Amended and Restated Venture Loan an Security Agreement among the Parties
and Horizon Technology Finance Corporation (the “Loan Amendment”); and

 

WHEREAS, the Parties wish to amend the terms
of the Agreement pursuant to Section 16.7 thereof and to agree to certain additional covenants and agreements set forth in this
Amendment.

 

NOW, THEREFORE, in consideration of the
mutual covenants and agreements contained herein and in the Loan Amendment and for other good and valuable consideration, the receipt
and sufficiency of which is hereby acknowledged, and intending to be legally bound hereby, the Parties hereby agree as follows:

 

1.                  
Earn-Out Payments. Section 7.2(a) and Section 7.2(b) of the Agreement are hereby deleted in their entirety and replaced
with the following:

 

(a) Subject to the terms of this
Agreement, with respect to each Calendar Year of the Agreement Term commencing on the later of (i) January 1, 2021 and (ii) the
one year anniversary of the DPT Project Completion Date (the “Earn-Out Commencement Date”) and ending on or
before March 31, 2033, Molteni shall pay Titan Earn-Out Payments on annual Net Sales of the Final Product in the Primary Territory
in each Calendar Year at the following rates:

 

	 	From
    (€)	To
    (€)	Earn-Out
    Payment (%) on Net Sales
	Tier 1	0	******	****%
	Tier 2	******	******	****%
	Tier 3	******	Beyond	****%

 

By way of example, €
***** total annual Net Sales of the Final Product in the Primary Territory shall be subject to Earn-Out Payments equal to
€ **** at ****% and € ***** at ****%, for a total payment for such year of € ****. For purposes of this
Section 7.2(a), “DPT Project Completion Date” shall mean the date on which the EU manufacturing compliance
project program at DPT Laboratories Ltd., dated September 2, 2019 (previously provided to Molteni on September 10, 2019) (the
“DPT Plan”) has been completed.

 

     

     

    

 

(b)       Subject
to the terms of this Agreement, with respect to each Calendar Year of the Agreement Term commencing on January 1, 2021 and ending
on or before March 31, 2033, Molteni shall pay Titan an Earn-Out Payment of ***** (****%) of Net Sales of any Competitor Product
sold by or on behalf of Molteni, its Affiliates, or any licensees in the Territory; provided, that, notwithstanding the foregoing,
no such payments shall accrue or be made with respect to any Net Sales of any Competitor Product sold on or before the Earn-Out
Commencement Date.

 

2.         Step-In Rights. The first sentence of Section 13.7 of the Agreement is hereby deleted in its entirety and replaced with
the following:

 

“In the event (a) of a material
disruption to any of the services to be performed by Titan under this Agreement, including those services contemplated by Article
4, Article 6 and Article 11 hereunder (the “Services”) (including a disruption due to Force Majeure), (b) of
repeated Services performance failures (provided that Molteni gives notice to Titan of such repeated Services performance failures
and Molteni’s intent to exercise its step in rights and provides Titan with a reasonable period, not to exceed thirty (30)
days, to cure such Services performance failures), (c) Titan states that it is unable to perform, or refuses to perform, any Services,
(d) Molteni is directed, or required, by a Law or Governmental Authority to step in, or (e) if the DPT Project Completion Date
has not occurred prior to December 31, 2019, Molteni may, in each case, act as agent of the Company, control, step in and supervise
or perform, or designate a Third Party to control, step in and supervise or perform, Titan’s performance of the impacted
Services or complete the DPT Plan, as applicable, until such time that Titan can demonstrate the ability to resume the performance
of such Services or, in solely the case of cause (e) above, the DPT Project Completion Date has occurred, as applicable (the date
Molteni steps-in, the “Step-In Date”).”

 

3.                  
Effectiveness and Ratification. All of the provisions of this Amendment shall be effective as of the Effective Date. Except
as specifically provided for in this Amendment, the terms of the Agreement remain in full force and effect unaffected by this Amendment.

 

4.                  
Effect of Amendment. Whenever the Agreement is referred to in the Agreement or in any other agreements, documents and instruments,
such reference shall be deemed to be to the Agreement as amended by this Amendment.

 

5.                  
Miscellaneous. Article 16 of the Agreement shall apply mutatis mutandis to this Amendment.

 

    2 

     

    

  

IN WITNESS WHEREOF, the undersigned have
executed this Amendment as of the date first above written.

 

	
         
	TITAN PHARMACEUTICALS, INC.
	 	 
	 	By:  	/s/ Sunil Bhonsle
	 	 	  Name: Sunil Bhonsle
	 	 	  Title: Chief Executive Officer
	 	 	 
	 	L. MOLTENI & C. DEI F.LLI ALITTI SOCIETÀ DI ESERCIZIO S.P.A.
	 	 
	 	By:	Gaetano Ievolella
	 	 	Name: Gaetano Ievolella
	 	 	Title: Chief Financial Officer

 

    3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}]]